126 related articles for article (PubMed ID: 29619416)
1. Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment.
Golden-Mason L; McMahan RH; Kriss MS; Kilgore AL; Cheng L; Dran RJ; Wieland A; Rosen HR
Hepatol Commun; 2018 Apr; 2(4):364-375. PubMed ID: 29619416
[TBL] [Abstract][Full Text] [Related]
2. Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients.
Jiang HJ; Wang XX; Luo BF; Cong X; Jin Q; Qin H; Zhang HY; Kong XS; Wei L; Feng B
Clin Exp Med; 2019 Aug; 19(3):299-308. PubMed ID: 31218578
[TBL] [Abstract][Full Text] [Related]
3. Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.
Spaan M; van Oord G; Kreefft K; Hou J; Hansen BE; Janssen HL; de Knegt RJ; Boonstra A
J Infect Dis; 2016 Jan; 213(2):216-23. PubMed ID: 26223768
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
[TBL] [Abstract][Full Text] [Related]
5. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.
Serti E; Chepa-Lotrea X; Kim YJ; Keane M; Fryzek N; Liang TJ; Ghany M; Rehermann B
Gastroenterology; 2015 Jul; 149(1):190-200.e2. PubMed ID: 25754160
[TBL] [Abstract][Full Text] [Related]
6. Restoration of natural killer cell activity by interferon-free direct-acting antiviral combination therapy in chronic hepatitis C patients.
Nakamura I; Furuichi Y; Sugimoto K
Hepatol Res; 2018 Oct; 48(11):855-861. PubMed ID: 29732688
[TBL] [Abstract][Full Text] [Related]
7. Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment.
Tang LS; Masur J; Sims Z; Nelson A; Osinusi A; Kohli A; Kattakuzhy S; Polis M; Kottilil S
World J Hepatol; 2016 Nov; 8(31):1318-1326. PubMed ID: 27872683
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3.
Yang CM; Yoon JC; Park JH; Lee JM
PLoS One; 2017; 12(4):e0175793. PubMed ID: 28410411
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
Fabbri G; Mastrorosa I; Vergori A; Mazzotta V; Pinnetti C; Grisetti S; Zaccarelli M; Ammassari A; Antinori A
BMC Infect Dis; 2017 Mar; 17(1):182. PubMed ID: 28249574
[TBL] [Abstract][Full Text] [Related]
11. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
Nguyen DT; Tran TTT; Nghiem NM; Le PT; Vo QM; Day J; Rahman M; Le HM
PLoS One; 2020; 15(5):e0233446. PubMed ID: 32433676
[TBL] [Abstract][Full Text] [Related]
13. Increased peripheral CD4
Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
[TBL] [Abstract][Full Text] [Related]
14. Markers of Natural Killer Cell Exhaustion in HIV/HCV Coinfection and Their Dynamics After HCV Clearance Mediated by Direct-Acting Antivirals.
Osegueda A; Polo ML; Baquero L; Urioste A; Ghiglione Y; Paz S; Poblete G; Gonzalez Polo V; Turk G; Quiroga MF; Laufer N
Open Forum Infect Dis; 2023 Dec; 10(12):ofad591. PubMed ID: 38107019
[TBL] [Abstract][Full Text] [Related]
15. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
16. Direct-acting Antiviral-induced Transient Recovery of NK Cells in Early-stage Treatment of Chronic Hepatitis C Patients.
Zhang X; Jiang Y; Li S; Bian D; Liu M; Kong M; Chen Y; Duan Z; Zheng S
J Clin Transl Hepatol; 2022 Dec; 10(6):1117-1124. PubMed ID: 36381106
[TBL] [Abstract][Full Text] [Related]
17. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.
Balistreri WF; Murray KF; Rosenthal P; Bansal S; Lin CH; Kersey K; Massetto B; Zhu Y; Kanwar B; German P; Svarovskaia E; Brainard DM; Wen J; Gonzalez-Peralta RP; Jonas MM; Schwarz K
Hepatology; 2017 Aug; 66(2):371-378. PubMed ID: 27997679
[TBL] [Abstract][Full Text] [Related]
18. Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.
Alao H; Cam M; Keembiyehetty C; Zhang F; Serti E; Suarez D; Park H; Fourie NH; Wright EC; Henderson WA; Li Q; Liang TJ; Rehermann B; Ghany MG
Hepatology; 2018 Dec; 68(6):2078-2088. PubMed ID: 29704252
[TBL] [Abstract][Full Text] [Related]
19. Effect of Combined HCV Therapy on Natural Killer Cell Activity.
Abd-Elsamie E; Kamal-ElDin TM; Hassaballa AE; A M; Badawy ER; ElMelegy TT; Zahran AM; Mekky MA
Egypt J Immunol; 2019 Jan; 26(1):151-161. PubMed ID: 31333005
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
